What Relaxo Footwears Holders Got Wrong Before The Slide

Relaxo Footwears looked like it had momentum, with analysts split between bullish urbanization and premiumization hopes and caution over digital execution and distribution friction. For Relaxo Footwears shareholders, the loss over the past year was 33.4%, including dividends. That drop now sits awkwardly beside Q1 2027 numbers that showed higher revenue and profit than Q1 2026. If you were weighing a purchase back in October 2025, what clues were already on the table?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

Relaxo Footwears has already moved. See which of 178 high quality undervalued stocks still trade below our estimates.

The Two Stories Investors Had To Weigh On Relaxo Footwears

The shares cost ₹438 at the start of the period, and anyone looking at Relaxo Footwears then had to decide which story felt more convincing.

On the optimistic side, the July 2025 bull Narrative put Fair Value at ₹741. That view leaned on data-driven distribution through the Parivaar app and premium product launches to support market share gains and margin improvement.

The July 2025 bear Narrative set Fair Value at ₹385. That case focused on risks from slow digital adoption, heavy reliance on low-cost footwear, and raw material volatility that could pressure earnings.

What The Results Put To The Test For Relaxo Footwears

The clearest datapoint was the Q1 2027 print. Relaxo Footwears reported revenue of ₹7,050.5m against ₹6,544.9m in Q1 2026, and net income of ₹549.4m versus ₹489m. Net margin edged up from 7.5% to 7.8%. That combination of higher sales, profit, and profitability leaned toward the optimistic thesis, although one quarter still left the broader debate open.

The hinge here was simple. Bulls and bears both anchored on whether premiumization and distribution reform would eventually show up in earnings quality. When you assess another retailer, track not just revenue and profit, but also whether margin is moving in the same direction as the story you were originally sold.

What Relaxo Footwears’ Lower Price Asks You To Believe

Relaxo Footwears now trades at ₹286, well below the ₹438 starting point from a year ago. The selected bullish Narrative still places its Fair Value above the current price, anchored in confidence around data-led distribution, premium ranges, and e-commerce execution.

For that higher figure to hold, a buyer today would need to believe premiumization and data-driven retail can lift earnings quality without relying on short term cost cuts.

"The shift to a more data-driven, distribution-led retail model (including rollout of the Relaxo Parivaar app and DMS) is expected to unlock higher efficiency, improve sales discipline, and drive better revenue quality through secondary sales, laying the groundwork for sustainable top-line improvement and margin expansion as network effects and channel transparency take hold."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Find Your Own Contrarian Opportunity

Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.

• Company 1 - 22% below our estimate - expands retail and pharmacy network while loyalty programs deepen recurring healthcare spending.
• Company 2 - 16% below our estimate - adds Nordic stores as online demand and sourcing changes reshape store economics and margins.
• Company 3 - 38% below our estimate - secures e-infrastructure and mega-project work supporting data center and manufacturing construction.

Three companies from the same screener. Open every one of the 204 solid balance sheet companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com